Brentuximab Vedotin Adds Benefit to A+AVD Therapy in cHL
Andrew M. Evens, DO, MSc, discusses the significance of the results from the phase III ECHELON-1 trial in which patients with stage III/IV classical Hodgkin lymphoma were treated with the combination of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine.
Andrew M. Evens, DO, MSc, director of the Lymphoma Program and associate director for Clinical Services at the Rutgers Cancer Institute of New Jersey, discusses the significance of the results from the phase III ECHELON-1 trial in which patients with stage III/IV classical Hodgkin lymphoma (cHL) were treated with the combination of brentuximab vedotin (Adcetris) plus doxorubicin, vinblastine, and dacarbazine (A+AVD).
The primary endpoint was progression-free survival (PFS). The trial results demonstrated an absolute improvement of 5% in PFS by independent review panel and 6.6% by investigator. The addition may be small, Evens notes, but it means that 20 patients need to be treated with the addition of brentuximab vedotin to prevent a modified PFS in 1 patient.
Examining the Non-Hodgkin Lymphoma Treatment Paradigm
July 15th 2022In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.
Listen
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More
